Yahoo Web Search

  1. ATE.V: Phase 2b Efficacy Data Expected in 4Q19…

    Zacks Small Cap Research via Yahoo FinanceAug 29 17:20 PM

    V) announced that the Phase 2b dose-ranging, efficacy study of ATB-346 had commenced. Study subjects will receive once daily doses of placebo or ATB-346 (150 mg, 200 mg, or 250 mg) over ...